safety

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn[...]

By sjmartinez • December 5, 2022

Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials

Hamid A, Anker MS, Ruckdeschel JC, Khan MS, Tharwani A, Oshunbade AA, Kipchumba RK, Thigpen SC, Anker SD, Fonarow GC, Hall ME, Butler J. Cardiovascular[...]

By sjmartinez • July 25, 2022